Aptadel Therapeutics raises €2M to develop its drug against Ewing sarcoma

BarcelonaAptadel Therapeutics has raised two million euros to continue developing its treatment for Ewing sarcoma, a childhood cancer with a very rapid progression and a low survival rate. The biotechnology company will continue working to bring its drug to patients. The drug is capable of halting metastasis and precisely targeting the interior of tumor cells. Aptadel is awaiting the completion of studies required by regulatory agencies such as the FDA and the EMA, which will allow it to begin its first clinical trials. With the funds raised, the company, headquartered in the Barcelona Science Park (PCB), has secured the support of the Japanese consultancy Newsight Tech Angels and has also strengthened the presence of the Little Warrior Foundation. The American investor, specializing in this pediatric disease, had already invested 480,000 euros in the company. Aptadel Therapeutics is thus preparing to close a Series A funding round, with which it aims to raise nine million euros. "This funding is crucial in the context of childhood cancer, an area with a significant medical impact but limited access to private funding," explained CEO Gisela Lorente. During 2025, the biotech She also received €450,000 from the Spanish Association Against Cancer (AECC).

Born in 2020 as spin-off From the Bellvitge Biomedical Research Institute (Idibell), the biotech company has already tested its therapy in cell and animal studies, confirming its ability to locate the tumor. "This funding will allow us to continue refining our product's behavior in the body to further enhance its effectiveness," Lorente emphasized. Ewing sarcoma is a very rare cancer that affects bones or the surrounding soft tissues and primarily develops in children and adolescents. Currently, available treatments, such as chemotherapy, are very aggressive and do not always halt the disease's progression. Aptadel Therapeutics is one of twelve Spanish companies developing new treatments for pediatric cancer based on a new generation of ribonucleic acid (RNA) molecules that allow for the selective targeting of tumor cells and reduce adverse effects.